September 10, 2025Cell Death and DiseaseOpen Access

Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway

View Full Paper

Ask AI

Bookmark

Authors

Discussion

In vitro and in vivo analysis shows chidamide and cytarabine reduce MYC signaling in acute myeloid leukemia, suggesting new therapeutic strategies.

Chidamide and cytarabine effectively target ribosome biogenesis in acute myeloid leukemia, showcasing a promising treatment strategy.
The combination significantly downregulates MYC signaling in acute myeloid leukemia, enhancing therapeutic outcomes.
Binding assays confirm that chidamide interacts with C-MYC, while cytarabine improves this interaction, promoting the treatment effect.
RRP9 was identified as a critical component of the MYC pathway, indicating its importance in acute myeloid leukemia prognosis.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

In vitro and in vivo analysis shows chidamide and cytarabine reduce MYC signaling in acute myeloid leukemia, suggesting new therapeutic strategies.